Article Sidebar

pdf
Date Published: 05/05/2025
Abstract Views: 61
Views pdf: 29
DOI: https://doi.org/10.51298/vmj.v549i3.13973
Issue
Vol. 549 No. 3 (2025)
Section
Các bài báo
How to Cite
Ngô Tuấn, M., Dương Quang, H., & Hồ Hữu, T. (2025). COMBINATION OF PLASMA CERULOPLASMIN mRNA AND FIBRINOGEN CHAIN A mRNA IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 549(3). https://doi.org/10.51298/vmj.v549i3.13973

COMBINATION OF PLASMA CERULOPLASMIN mRNA AND FIBRINOGEN CHAIN A mRNA IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA

Minh Ngô Tuấn, Huy Dương Quang, Thọ Hồ Hữu

Main Article Content

Abstract

Objective: To investigate the value of combining plasma Ceruloplasmin mRNA and Fibrinogen Chain A mRNA in the diagnosis of hepatocellular carcinoma (HCC). Subjects and methods: To survey 131 HCC patients, 70 chronic liver disease (CHD) patients, and 41 healthy people (HD) at 103 Military Hospital from 5/2020 to 6/2024. Determination of plasma CP mRNA and FGA mRNA expression levels by Semi-nested quantitative RT-PCR technique and survey of the value of combining the two markers for diagnostic HCC compared to the control group. Results: The combination of CP mRNA and FGA mRNA has the value of distinguishing HCC from non-HCC (AUC of the general control, CHD, and HD groups are 0.84, 0.79 and 0.96, respectively). The diagnostic value when combining CP mRNA and FGA mRNA for HCC with AFP ≤ 20ng/mL, the general control group is at a good level (AUC = 0.82), the CHD control group is at a moderate level (AUC = 0.75), and the HD control group is at a very good level (AUC = 0.96). Conclusion: The combination of CP mRNA and FGA mRNA has quite good diagnostic efficiency for HCC and HCC with AFP < 20 ng/ml compared with the control group.

Article Details

Keywords

Hepatocellular carcinoma, CP mRNA, FGA mRNA

References

1. Bray F., Laversanne M., Sung H., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 74(3): 229-63.
2. Singal A. G., Llovet J. M., Yarchoan M., et al. (2023). AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 78(6): 1922-65.
3. Kudo M., Kawamura Y., Hasegawa K., et al. (2021). Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 10(3): 181-223.
4. Roskams-Hieter B., Kim H. J., Anur P., et al. (2022). Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies. NPJ Precis Oncol, 6(1): 28.
5. Mukhopadhyay C. K., Attieh Z. K., Fox P. L. (1998). Role of ceruloplasmin in cellular iron uptake. Science, 279(5351): 714-7.
6. Zanetto A., Campello E., Spiezia L., et al. (2018). Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. Cancers (Basel), 10(11).
7. Nguyen H. B., Le X. T., Nguyen H. H., et al. (2022). Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-γ-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related. Cancer Inform, 21: 11769351221100730.
8. Wang T., Zhang K. H. (2020). New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol, 10: 1316.